Contributions
Abstract: 253
Type: Oral
In people who have had a clinically isolated syndrome (CIS) suggestive of MS, clinical outcomes are highly variable and depend on the duration of follow-up. For example conversion to MS occurs mostly in the first decade following a CIS, while secondary progressive MS usually becomes apparent in the second or third decades. With increasing interest in the use of MS disease modifying treatments in people who have had a CIS, awareness of long-term clinical outcomes may help to inform treatment choices. Few longitudinal CIS studies have assessed clinical outcomes over more than a decade, and so it remains uncertain what proportion ultimately develop MS on clinical or radiological grounds, what proportion develop progressive disease, and how long after a CIS such outcomes can be predicted or become apparent. The first London CIS cohort was recruited in the 1980's and has subsequently been assessed clinically and radiologically 1, 5, 10, 14 and 20 years later. In this session, we will present the findings from the latest (30 year) follow-up of this cohort.
Disclosure: Declan Chard has received research support from the MS Society of Great Britain and Northern Ireland, and the National Institute for Health Research University College London Hospitals Biomedical Research Centre. He has received honoraria (paid to his employer) from Ismar Healthcare NV, Swiss MS Society, Excemed (previously Serono Symposia International Foundation), Merck, Bayer and Teva for faculty-led education work; Teva for advisory board work; meeting expenses from Merck, MS Trust, National MS Society, Novartis, Société des Neurosciences and Teva; and has previously held stock in GlaxoSmithKline.
Abstract: 253
Type: Oral
In people who have had a clinically isolated syndrome (CIS) suggestive of MS, clinical outcomes are highly variable and depend on the duration of follow-up. For example conversion to MS occurs mostly in the first decade following a CIS, while secondary progressive MS usually becomes apparent in the second or third decades. With increasing interest in the use of MS disease modifying treatments in people who have had a CIS, awareness of long-term clinical outcomes may help to inform treatment choices. Few longitudinal CIS studies have assessed clinical outcomes over more than a decade, and so it remains uncertain what proportion ultimately develop MS on clinical or radiological grounds, what proportion develop progressive disease, and how long after a CIS such outcomes can be predicted or become apparent. The first London CIS cohort was recruited in the 1980's and has subsequently been assessed clinically and radiologically 1, 5, 10, 14 and 20 years later. In this session, we will present the findings from the latest (30 year) follow-up of this cohort.
Disclosure: Declan Chard has received research support from the MS Society of Great Britain and Northern Ireland, and the National Institute for Health Research University College London Hospitals Biomedical Research Centre. He has received honoraria (paid to his employer) from Ismar Healthcare NV, Swiss MS Society, Excemed (previously Serono Symposia International Foundation), Merck, Bayer and Teva for faculty-led education work; Teva for advisory board work; meeting expenses from Merck, MS Trust, National MS Society, Novartis, Société des Neurosciences and Teva; and has previously held stock in GlaxoSmithKline.